Home Mechanisms of acquired resistance to anti-EGFR targeted therapies in metastatic colorectal cancer Figure 4. PDX from a relapsed patient is sensitive to combinatorial treatment

Figure 4. PDX from a relapsed patient is sensitive to combinatorial treatment

Newsstand

  • Supplemento al n.8 - Ottobre 2023 NCF International 2023
Newsstand
© © 2023 Tecniche Nuove Spa - All rights reserved. Registered office: Via Eritrea 21 - 20157 Milan. Share capital: 5,000,000 Euro fully paid up. Tax code, VAT number and registration with the Milan Register of Companies: 00753480151